Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley says.
‘China’s Ozempic’ may vie with Eli Lilly, Novo Nordisk for global weight-loss drug market
RELATED ARTICLES
In A.I. Boom, Venture Capital Firms Are Raising Loads More Money
Russia Can Play Important Role in Resolving Situation Around Iran Nuclear Program – Grossi
EU Plan to Seize Russian Assets Aims to Fuel Ukraine Conflict – Hungarian FM
